MLYS vs. ANAB, DNTH, WVE, NRIX, NUVB, BCYC, SVRA, PAHC, IRON, and AUPH
Should you be buying Mineralys Therapeutics stock or one of its competitors? The main competitors of Mineralys Therapeutics include AnaptysBio (ANAB), Dianthus Therapeutics (DNTH), Wave Life Sciences (WVE), Nurix Therapeutics (NRIX), Nuvation Bio (NUVB), Bicycle Therapeutics (BCYC), Savara (SVRA), Phibro Animal Health (PAHC), Disc Medicine (IRON), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical preparations" industry.
AnaptysBio (NASDAQ:ANAB) and Mineralys Therapeutics (NASDAQ:MLYS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, community ranking, media sentiment and profitability.
84.5% of Mineralys Therapeutics shares are held by institutional investors. 33.7% of AnaptysBio shares are held by company insiders. Comparatively, 33.2% of Mineralys Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Mineralys Therapeutics has a net margin of 0.00% compared to Mineralys Therapeutics' net margin of -711.17%. AnaptysBio's return on equity of -32.48% beat Mineralys Therapeutics' return on equity.
AnaptysBio presently has a consensus target price of $46.38, indicating a potential upside of 84.98%. Mineralys Therapeutics has a consensus target price of $33.50, indicating a potential upside of 157.69%. Given AnaptysBio's stronger consensus rating and higher probable upside, analysts clearly believe Mineralys Therapeutics is more favorable than AnaptysBio.
AnaptysBio has a beta of -0.32, indicating that its share price is 132% less volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500.
AnaptysBio received 341 more outperform votes than Mineralys Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Mineralys Therapeutics an outperform vote while only 65.61% of users gave AnaptysBio an outperform vote.
Mineralys Therapeutics has lower revenue, but higher earnings than AnaptysBio. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.
In the previous week, AnaptysBio had 2 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 5 mentions for AnaptysBio and 3 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.22 beat AnaptysBio's score of 0.99 indicating that AnaptysBio is being referred to more favorably in the media.
Summary
Mineralys Therapeutics beats AnaptysBio on 10 of the 17 factors compared between the two stocks.
Get Mineralys Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MLYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mineralys Therapeutics Competitors List
Related Companies and Tools
